{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:39:27Z","timestamp":1787060367783,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Sequential or combined treatment with nucleos(t)ide analogs (NAs) and pegylated interferon alpha-2b (Peg-IFN-\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -2b) can improve the clinical cure rate. However, its clinical application is limited due to the adverse reactions associated with IFN.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A multi-center prospective observational study was conducted involving 59 NAs-treated chronic hepatitis B (CHB) patients who were treated with a combination therapy of NAs and Peg-IFN-\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -2b for 48\u202fweeks. Another 327 NAs-treated patients received NAs monotherapy for 48\u202fweeks. At the end of the treatment, patients were classified into either the clinically cured group or the non-clinically cured group based on clinical efficacy. The study aimed to analyze the clinical cure rate and the predictive factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After propensity score matching (PSM), a total of 104 patients were included in the exposure and the control groups. After 48\u202fweeks of treatment, 13 patients in the exposed group achieved clinical cure, with a cure rate of 25%. In contrast, in the control group was 1.92%. The clinical cure rate was greater in the population with CHB or compensated cirrhosis treated with sequential or combined Peg-IFN-\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -2b and NAs than in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Patients treated with Peg-IFN-\u03b1-2b were divided into a clinical cure group and a non-clinical cure group for single-factor regression and multi-factor binary logistic regression. The results showed that baseline qHBsAg [relative ratio (RR)\u202f=\u202f0.997, 95%CI: [0.995, 0.999],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.031] and \u25b3TBiL (RR\u202f=\u202f0.698, 95%CI: [0.555, 0.879],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.002) were independent influencing factors for achieving clinical cure in patients with CHB or compensated cirrhosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A lower baseline qHBsAg and decrease in TBiL at 24\u202fweeks of treatment are independent influencing factors for achieving clinical cure. The lower the baseline qHBsAg and the higher the \u25b3TBiL levels after 24\u202fweeks of treatment, the higher the probability of patients achieving clinical cure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1483744","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:12:22Z","timestamp":1736385142000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive factors for clinical cure in the treatment of HBeAg(\u2212) chronic hepatitis B or compensated cirrhosis: a prospective observational study"],"prefix":"10.3389","volume":"11","author":[{"given":"Yan-Qing","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Fan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.3389\/fmicb.2022.980250","article-title":"Effect of pegylated interferon-\u03b12b add-on therapy on renal function in chronic hepatitis B patients: a real-world experience","volume":"13","author":"Peng","year":"2022","journal-title":"Front Microbiol"},{"key":"ref2","year":"2021"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1080\/22221751.2022.2100831","article-title":"Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy","volume":"11","author":"Li","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","article-title":"Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen \u2264 1500 IU\/mL: an observational study","volume":"26","author":"Wu","year":"2020","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.3969\/j.issn.1672-5069.2023.03.040","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"26","author":"You","year":"2023","journal-title":"J Prac Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"997608","DOI":"10.3389\/fimmu.2022.997608","article-title":"Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"894410","DOI":"10.3389\/fimmu.2022.894410","article-title":"Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-\u03b1 in NA-suppressed chronic hepatitis B patients","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/j.cgh.2021.04.031","article-title":"Switching to or add-on Peginterferon in patients on Nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT","volume":"20","author":"Lim","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/jvh.13722","article-title":"Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients","volume":"29","author":"Chu","year":"2022","journal-title":"J Viral Hepat"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12072-019-09956-1","article-title":"Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the endeavor study","volume":"13","author":"Wu","year":"2019","journal-title":"Hepatol Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2022.892031","article-title":"Dynamic changes of cytokine profiles and Virological markers associated with HBsAg loss during Peginterferon alpha-2a treatment in HBeAg-positive chronic hepatitis B patients","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12876-017-0657-y","article-title":"Addition of nucleoside analogues to peg-IFN\u03b1-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFN\u03b1-2a: a randomized controlled trial","volume":"17","author":"Xu","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1365-2036.2005.02453.x","article-title":"The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation","volume":"21","author":"Van Zonneveld","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jvh.13151","article-title":"Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha\u2013based therapy","volume":"26","author":"Li","year":"2019","journal-title":"J Viral Hepat"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1243462","DOI":"10.1016\/S2468-1253(16)30189-3","article-title":"Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial","volume":"2","author":"Bourli\u00c3","year":"2017","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3350\/cmh.2021.0093","article-title":"Toward a complete cure for chronic hepatitis B: novel therapeutic targets for hepatitis B virus","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12876-021-02038-3","article-title":"FIB-4, APRI, and AST\/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran","volume":"21","author":"Amernia","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3969\/j.issn.1001-5256.2023.08.009","article-title":"Effect of pegylated interferon \u03b1-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B","volume":"39","author":"Li","year":"2023","journal-title":"J Clin Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/jvh.13571","article-title":"Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B na\u00efve patients","volume":"28","author":"Li","year":"2021","journal-title":"J Viral Hepat"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/apt.15098","article-title":"Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B","volume":"49","author":"Liem","year":"2019","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1483744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:12:25Z","timestamp":1736385145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1483744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":27,"alternative-id":["10.3389\/fmed.2024.1483744"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1483744","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"article-number":"1483744"}}